<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS, Rundell KW, Silvers WS, Storms WW, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Schuller DE, Spector SL, Tilles SA, Wallace D, Henderson W, Schwartz L, Kaufman D, Nsouli T, Shieken L, Rosario N, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. 2010 Dec;105(6 Suppl):S1-47. [493 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21167465&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic obstructive asthma, unspecified  (493.20); Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); General physical examination  (89.7); Rhinoscopy  (21.21)"/><FieldValue Value="MSH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Anti-Asthmatic Agents ; Ascorbic Acid ; Asthma ; Asthma, Exercise-Induced ; Athletes ; Bronchial Provocation Tests ; Bronchoconstriction ; Bronchodilator Agents ; Cholinergic Antagonists ; Cromolyn Sodium ; Diagnosis, Differential ; Diet, Sodium-Restricted ; Dietary Supplements ; Echocardiography ; Electrocardiography ; Electrocardiography, Ambulatory ; Exercise ; Fish Oils ; Histamine Antagonists ; Ipratropium ; Leukotriene Antagonists ; Mannitol ; Medical History Taking ; Methacholine Compounds ; Physical Examination ; Respiratory Function Tests ; Risk Reduction Behavior ; Sports ; Sports Medicine ; Xanthines "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Anticholinergic Agents ; Ascorbic Acid ; Asthma ; Athletes ; Bronchoconstriction ; Cholinergic Antagonists ; Cromolyn Sodium ; Dietary Supplements ; Differential Diagnosis ; Echocardiography ; Electrocardiography ; Electrocardiography, Ambulatory ; Exercise ; Fish Oils ; Histamine Antagonists ; Holter Monitors ; Hyperpnea ; Leukotriene Antagonists ; Low sodium diet ; Mast cell stabilizer ; methylxanthine ; physical examination ; Respiratory Function Tests ; Sports ; sports medicine specialty ; Xanthines "/><FieldValue Value="PDQ: ascorbic acid ; mannitol "/><FieldValue Value="SNOMEDCT_US: Ambulatory ECG  (164850009); Antiasthmatic agent  (360253007); Anticholinergic agent  (14601000); Anticholinergic agent  (373246003); Ascorbic acid  (43706004); Ascorbic acid  (46123006); Asthma  (195967001); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Bronchial provocation test  (165011001); Bronchial provocation test  (252518009); Bronchodilator  (353866001); Bronchodilator  (372580007); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Cromolyn sodium  (387221005); Cromolyn sodium  (40652001); Differential diagnosis  (47965005); Echocardiography  (40701008); Electrocardiographic monitor and recorder  (86184003); Electrocardiographic procedure  (29303009); Endoscopy of nose  (25570002); Excercise bronchial provocation test  (446461001); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Exercise challenge  (128967005); Exercise-induced asthma  (31387002); Fish oils  (346441008); Hyperpnea  (180928006); Ipratropium  (108624006); Ipratropium  (372518007); Ipratropium bromide  (386881005); Leukotriene receptor inhibitor  (108616001); Leukotriene receptor inhibitor  (372517002); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Mannitol  (30761007); Mannitol  (387168006); Mast cell stabilizer  (108860003); Mast cell stabilizer  (372553000); Measurement of respiratory function  (23426006); Methacholine challenge  (252520007); Methyl xanthine  (259553003); Nutritional supplement  (108961000); Nutritional supplement  (226279009); Nutritional supplement  (373453009); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pre-exercise state  (128977007); Rhinoscope  (111048002); Rhinoscope  (465082001); Sport  (14468000); Sport  (415577004); Utilization of mannitol test  (45337004)"/><FieldValue Value="UMD: Nasoscopes  (12-710); Physiologic Monitor Modules, Electrocardiography  (20-771); Recorders, Electronic Storage, Data, Electrocardiography, Loop-Recording, External  (24-250); Scanning Systems, Ultrasonic, Cardiac  (17-422)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Exercise-induced bronchoconstriction (EIB) with or without chronic asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Allergy and Immunology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pediatrics" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Sports Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To empower health care specialty practitioners to provide outstanding health care services to their patients in diagnosing and managing exercise-induced bronchoconstriction (EIB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide the most up-to-date, evidence-based information and recommendations on the diagnosis and management of EIB &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients having or suspected of having exercise-induced bronchoconstriction (EIB), with or without chronic asthma, including recreational and elite athletes and nonathletes&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;History and physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary function tests pre- and postbronchodilator &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Indirect challenge&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Exercise challenge with dry air &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Eucapnic voluntary hyperpnea (EVH) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mannitol challenge &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sports-specific field challenge &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methacholine challenge &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Differential diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Further evaluation including electrocardiogram (ECG), echocardiography, Holter monitor, and exercise rhinoscopy as indicated &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management/Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Avoidance of triggers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled corticosteroids &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inhaled short- and long-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonists (given as single dose or on an intermittent basis) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Leukotriene inhibitors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mast cell stabilizers (e.g., cromolyn sodium) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticholinergic agents (e.g., ipratropium bromide) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methylxanthines, antihistamines, and other agents &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nonpharmacologic therapy (preexercise warm-up, reduction of sodium intake, and ingestion of fish oil and ascorbic acid supplementation) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity, specificity, and positive predictive values of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prevalence of exercise-induced bronchoconstriction (EIB) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptom improvement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary function (forced expiratory volume in 1 second [FEV&lt;sub&gt;1&lt;/sub&gt;]) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A search of the medical literature was performed for terms relevant to this practice parameter including: exercise-induced asthma, exercise-induced bronchoconstriction (EIB), bronchoconstriction, asthma, exercise challenge test, mannitol, methacholine, randomized control trials involving inhaled corticosteroids, leukotriene receptor antagonists, mast cell inhibitors, short-acting and long-acting beta agonists, short-acting anticholinergics, differential diagnosis, vocal cord dysfunction, elite athletes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Literature searches were performed using MEDLINE, EMBASE, EBM reviews, Cochrane Central Register of Control Trials, AMED, PsycINFO, PASCAL, CINAHL, SPORTDiscus with Full Text, Academic Search Elite, Web of Science, BIOSIS Previews, PUBMED, SCOPUS, and Cochrane Airways Register. Hand searches were also done of respiratory journals, meeting abstracts, and conference proceedings from key scientific meetings. Reference lists of included studies were also searched.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All reference types were included in the results. References from 1960 until at least June 2010 were included. Although the ideal type of reference would be a randomized, double-blind, placebo-controlled study, not all studies met this criteria. Consequently it was necessary to review a number of observational studies along with basic laboratory studies to develop a complete document on this topic. Only English language articles were included.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Workgroup members, all of whom were experts in the area of EIB, contributed additional manuscripts to the list.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Category of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ia&lt;/strong&gt; Evidence from meta-analysis of randomized controlled trials&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ib&lt;/strong&gt; Evidence from at least 1 randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IIa&lt;/strong&gt; Evidence from at least 1 controlled study without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IIb&lt;/strong&gt; Evidence from at least 1 other type of quasi-experimental study&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Evidence from nonexperimental descriptive studies, such as comparative studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IV&lt;/strong&gt; Evidence from expert committee reports or opinions or clinical experience of respected authorities or both&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Published clinical investigations were rated by category of evidence and the strength of clinical recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This document was developed by a Workgroup under the aegis of the Joint Task Force on Practice Parameters. Three national allergy and immunology organizations&amp;mdash;the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), and the Joint Council of Allergy, Asthma and Immunology (JCAAI)&amp;mdash;have authorized the Joint Task Force to develop new parameters and update existing parameters. The document was written, edited, and reviewed by specialists in the discipline of allergy/immunology and was exclusively funded by the allergy and immunology organizations noted above.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; Directly based on category I evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; Directly based on category II evidence or extrapolated recommendation from category I evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; Directly based on category III evidence or extrapolated recommendation from category I or II evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;LB&lt;/strong&gt; Laboratory based&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;After the Joint Task Force completed its review and editing of the manuscript, subject matter experts in the field of allergy and immunology and exercise-induced bronchoconstriction (EIB) were recruited to review the manuscript. These expert reviewers were appointed by the American Academy of Allergy, Asthma and Immunology (AAAAI), and the American College of Allergy, Asthma and Immunology (ACAAI). The authors of the document then diligently reviewed and evaluated additional comments and suggestions from these reviewer experts. The revised final document presented here was approved by the sponsoring organizations and reflects an evidence-based and generally accepted consensus parameter on the diagnosis and management of EIB encompassing the most contemporary evidence-based understanding of the pathogenesis, prevalence, clinical presentation, diagnosis, differential diagnosis, and treatment (both nonpharmaceutical and pharmaceutical) of patients having or suspected of having EIB, with or without chronic asthma, in recreational and elite athletes and nonathletes.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline recommendations are presented in the form of summary statements. After each statement is a letter in parentheses that indicates the strength of the recommendation. Strength of recommendations (&lt;strong&gt;A-D&lt;/strong&gt; and &lt;strong&gt;LB&lt;/strong&gt;) and categories of evidence (&lt;strong&gt;Ia, Ib, IIa, IIb, III, IV&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An algorithm for the appropriate use of allergen immunotherapy is also provided in the original guideline document. Given below are annotations for use with that algorithm.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Annotations&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;History, physical examination, and pulmonary function tests pre- and postbronchodilator (with flow volume loops, and pre/postbronchodilator functions) are necessary if there is suspicion of asthma or exercise-induced bronchoconstriction (EIB). History alone should not be used to diagnose or exclude the diagnosis of EIB. If pulmonary function equipment (i.e., spirometry) is not available in the clinic setting, patients should be referred to a pulmonary function laboratory or to a physician with office spirometry equipment. Peak flow is a poor surrogate for diagnosis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;and 3. Expert consensus is, if baseline forced expiratory volume in 1 second (FEV&lt;sub&gt;1&lt;/sub&gt;) is 70% predicted value, exercise challenge with dry air and eucapnic voluntary hyperpnea (EVH) should not be done for safety reasons. Other challenges (e.g., exercise without the use of dry air, mannitol) should be performed with caution if baseline FEV&lt;sub&gt;1&lt;/sub&gt; is 70% predicted value. Eucapnic voluntary hyperpnea may be a surrogate for exercise, especially for those who cannot exercise or for elite athletes; however, EVH can elicit a severe response. Inhalation of dry air as part of the exercise protocol is strongly recommended to diagnose or exclude EIB because it increases sensitivity to the challenge. Mannitol challenge is currently approved in 23 countries including the United States. More than one indirect challenge may be required for diagnosis if a first challenge is negative. When predicted spirometry values are obtained outside of the range of the algorithm, judgment must be used when interpreting the results. Care must be taken when evaluating patients who are unusually tall or short, in particular, and have a predicted FEV&lt;sub&gt;1&lt;/sub&gt; that is 70%. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;If indirect challenge is negative, then a field challenge to reproduce signs and symptoms of the exercise-induced bronchospasm is recommended. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If indirect challenge is positive, therapy with albuterol as needed with avoidance of triggers for EIB may be indicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If field challenge is negative but the patient is still symptomatic, a methacholine challenge may be performed to rule out bronchial hyperresponsiveness (BHR). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If methacholine challenge is positive, controller medications, including inhaled steroids, should be considered for probable asthma in conjunction with avoidance of triggers and use of albuterol as needed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If methacholine challenge is negative, a different diagnosis should be considered. An extensive differential diagnosis should be considered if the evaluation (including history, physical examination, pulmonary function testing pre and post bronchodilator, exercise challenge, and methacholine) is not consistent with EIB. The differential diagnosis encompasses physiologic limitations including vocal cord dysfunction (VCD), exercise dyspnea, anxiety, obesity or a gradient of poor conditioning, or cardiac abnormalities (e.g., tachycardia, idiopathic hypertrophic subaortic stenosis, hyperventilation syndrome, pulmonary arteriovenous malformation). The further evaluation may include electrocardiogram (ECG), echocardiography, Holter monitor, and exercise rhinoscopy as indicated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the controller medication is ineffective, then the steps described in Annotation 8 above should be followed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the controller medication is effective, challenge should be performed to document EIB if the FEV&lt;sub&gt;1&lt;/sub&gt; after controller therapy is greater than 70%. If the FEV&lt;sub&gt;1&lt;/sub&gt; is not greater than 70%, additional consideration should be given to different diagnoses. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Summary Statements&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pathophysiology of EIB&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Definition and Overview&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;EIB is defined as the transient narrowing of the lower airways that occurs after vigorous exercise. It may appear with or without asthma. The term exercise-induced asthma (EIA) should not be used because exercise does not induce asthma but rather is a trigger of bronchoconstriction. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EIB occurs in response to heating and humidifying large volumes of air during a short period. The most important determinants of expression of EIB response and severity are the water content of the inspired air and/or the level of ventilation achieved and sustained during exercise. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Respiratory water loss at high ventilation is associated with airway cooling and dehydration and an increase in osmolarity of the airway surface. (&lt;strong&gt;B&lt;/strong&gt;) The predominant theory of EIB is the osmotic theory, although the thermal theory may also play a role. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise itself is not necessary to cause airways to narrow; voluntary hyperpnea of dry air may induce bronchoconstriction similar to exercise. Eucapnic voluntary hyperpnea is used as a surrogate for exercise in the diagnosis of EIB, particularly in athletes. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;People who have EIB without asthma associated with airway inflammation and the presence of eosinophils are likely to be responsive to corticosteroids. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EIB is accompanied by release of mediators such as prostaglandins (PGs), leukotrienes (LTs), and histamine. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In approximately half of patients who have EIB, there is an interval of refractoriness lasting approximately 2 to 3 hours immediately after an episode of EIB during which additional exercise produces little or no bronchoconstriction. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Genetics and Environment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;Gene expression and environmental interaction may be relevant to the EIB phenotype. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oxidative stress caused by environmental pollutants that are inhaled during exercise may play an important role in the development and exaggeration of EIB. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The pathogenesis of EIB in elite athletes may relate to effects on the airways arising from humidifying large volumes of dry air over months of training with or without exposure to environmental irritants, allergens, and viral agents. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prevalence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;11&quot;&gt;&#xD;&#xA;    &lt;li&gt;EIB is reported in most asthmatic patients. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with more severe or less well-controlled asthma are more likely to manifest EIB than patients with less severe or better controlled disease. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The true prevalence of EIB in the general population is poorly defined because epidemiologic studies of EIB have not differentiated asthmatic vs. nonasthmatic populations. In addition, there is no consensus for the end point indicative of a positive response, and the conditions under which exercise is performed frequently differ. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The prevalence of EIB in elite athletes appears to be higher than in the general population and depends on the type of sport, the maximum exercise level, and environmental conditions. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The prevalence of EIB varies with history, type of challenge, and conditions under which the challenge is performed. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The prevalence of EIB with and without asthma may be influenced by age, sex, and ethnicity. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;17&quot;&gt;&#xD;&#xA;    &lt;li&gt;Self-reported symptoms alone are not reliable for diagnosis of EIB. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optimal EIB management may require confirmation of the diagnosis using objective methods. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Self-reported symptom-based diagnosis of EIB in the elite athlete lacks sensitivity and specificity and establishes the necessity for standardized, objective challenges using spirometry. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The indirect challenge (e.g., exercise or surrogate such as EVH) is preferred over a direct challenge (e.g., methacholine) for assessing EIB in the elite athlete. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EVH is the preferred surrogate challenge for the elite athlete participating in competitive sports. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The intensity of the exercise challenge for the elite athlete should be 95% or greater than actual or estimated maximal heart rate (HR&lt;sub&gt;max&lt;/sub&gt;), and dry medical-grade air should be used in performing the challenge. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperosmolar aerosols may also be used as surrogates to exercise. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Differential Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;24&quot;&gt;&#xD;&#xA;    &lt;li&gt;Exercise-induced laryngeal dysfunction (EILD), primarily VCD and other glottic abnormalities, may be elicited by exercise and mimic EIB. Inspiratory stridor is a differentiating hallmark sign with EILD and not with EIB alone. Flattening of the inspiratory curve on spirometric maneuver may be seen concomitant with symptoms. EILD may occur alone or with EIB. Failure to respond to asthma management is a key historical feature suggesting EILD. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise-induced dyspnea and hyperventilation can masquerade as asthma, especially in children and adolescents. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Shortness of breath with exercise may be associated with underlying conditions due to obstructive lung disease, such as chronic obstructive pulmonary disease (COPD), or restrictive lung physiology, such as obesity, skeletal defects (e.g., pectus excavatum), diaphragmatic paralysis, and interstitial fibrosis. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Shortness of breath accompanied by pruritus and urticaria, with varying other systemic symptoms, suggests exercise-induced anaphylaxis (EIAna) rather than EIB. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the absence of objective evidence of EIB, breathlessness with exercise, with or without chest pain, may be caused by cardiovascular, pulmonary, or gastroenterologic mechanisms other than asthma. Appropriate cardiopulmonary testing and/or referral to a cardiologist, pulmonologist, or gastroenterologist may be necessary. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise-induced dyspnea is seen as a physiologic limitation in otherwise healthy active individuals without bronchospasm. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The association between EIB and gastroesophageal reflux disease (GERD) is controversial, and probably there is no relationship. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychological factors need to be considered in the differential diagnosis of EIB. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dyspnea on exertion, which is prevalent in otherwise healthy, obese individuals, is not associated with EIB. (&lt;strong&gt;C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mitochondrial enzyme deficiency with myopathy is a rare cause of exercise limitation. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Introduction&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;34&quot;&gt;&#xD;&#xA;    &lt;li&gt;Frequent EIB in asthmatic patients suggests inadequate asthma control and requires patient re-evaluation to determine the need for additional therapy. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Failure of appropriate pharmacotherapeutic agents to prevent EIB indicates the need to re-evaluate the diagnosis. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Several pharmacotherapeutic agents are effective when given for the prevention or attenuation of EIB. They differ in their mechanisms of action and overall effectiveness. In addition, there is both intrapatient and interpatient variability in responsiveness. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medications may differ in effectiveness over time because of variability of asthma, environmental conditions, intensity of the exercise stimulus, and tachyphylaxis. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;&amp;beta;&lt;sub&gt;2&lt;/sub&gt;-Adrenergic Receptor Agonists&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;38&quot;&gt;&#xD;&#xA;    &lt;li&gt;Inhaled &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-adrenergic receptor agonists are the most effective group of agents for short-term protection against EIB and for accelerating recovery of FEV&lt;sub&gt;1&lt;/sub&gt; to baseline when given after a decrease in FEV&lt;sub&gt;1&lt;/sub&gt; after exercise. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When given as a single dose or on an intermittent basis, short-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonists (SABAs) and long-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonists (LABAs) may protect against or attenuate EIB; SABAs are usually effective for 2 to 4 hours and LABAs for up to 12 hours. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Daily use of &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-adrenergic agents alone or in combination with inhaled corticosteroids (ICS) usually will lead to tolerance manifested as a reduction in duration and/or magnitude of protection against EIB and a prolongation of recovery in response to SABA after exercise. Therefore, monotherapy with adrenergic agents is generally recommended for use only on an intermittent basis for prevention of EIB. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Regular (i.e., daily) use of &amp;beta;2-agonists for EIB leads to relative loss of efficacy of the agent. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Leukotriene (LT) Inhibitors&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;42&quot;&gt;&#xD;&#xA;    &lt;li&gt;Daily therapy with LT inhibitors does not lead to tolerance and can be used for intermittent or maintenance prophylaxis; however, it provides protection that may not be complete and has no use to reverse airway obstruction when it occurs. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mast Cell Stabilizers&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;43&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cromolyn sodium and nedocromil sodium (currently not available in the United States in an inhaled form) when inhaled shortly before exercise attenuate EIB but have a short duration of action. They do not have a bronchodilator activity. They may be effective alone or as added therapy with other drugs for EIB. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Inhaled Corticosteroids&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;44&quot;&gt;&#xD;&#xA;    &lt;li&gt;Although ICS therapy can decrease the frequency and severity of EIB, its use does not necessarily eliminate the need for additional acute therapy with &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-adrenergic agonists or other agents. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ICS therapy does not prevent the occurrence of tolerance from daily &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonist use. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Anticholinergic Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;46&quot;&gt;&#xD;&#xA;    &lt;li&gt;Although ipratropium bromide has been inconsistent in attenuating EIB, a few patients may be responsive to this agent. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Methylxanthines, Antihistamines, and Other Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;47&quot;&gt;&#xD;&#xA;    &lt;li&gt;Drugs in several other pharmacotherapeutic classes, including theophylline, antihistamines, calcium channel blockers, &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-adrenergic receptor antagonists, inhaled furosemide, heparin, and hyaluronic acid, have been examined for actions against EIB with inconsistent results. (&lt;strong&gt;B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Nonpharmacologic Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;48&quot;&gt;&#xD;&#xA;    &lt;li&gt;Preexercise warm-up may be helpful in reducing the severity of EIB. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction of sodium intake and ingestion of fish oil and ascorbic acid supplementation may be helpful in reducing the severity of EIB. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Competitive and Elite Athletes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;50&quot;&gt;&#xD;&#xA;    &lt;li&gt;EIB alone in elite athletes may have different characteristics than EIB with asthma in elite athletes or EIB in the general population. These divergent characteristics may include pathogenesis, presentation, diagnosis, management, and the requirement by governing bodies to obtain permission to receive pharmaceutical agents. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Airway inflammation in elite athletes may be related to the high intensity of physical training, high minute ventilation, and inhalation of airborne pollutants and allergens. (&lt;strong&gt;D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The diagnosis of EIB, whether alone or with asthma, in elite athletes may be difficult because history and presentation are not reliable. Objective testing is necessary to diagnose the condition accurately. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In general, the treatment of EIB in patients who have asthma is similar in both recreational and elite athletes. However, the efficacy of therapy for EIB alone in athletes at any level is not well established. (&lt;strong&gt;A&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Category of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ia&lt;/strong&gt; Evidence from meta-analysis of randomized controlled trials&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ib&lt;/strong&gt; Evidence from at least 1 randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IIa&lt;/strong&gt; Evidence from at least 1 controlled study without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IIb&lt;/strong&gt; Evidence from at least 1 other type of quasi-experimental study&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Evidence from nonexperimental descriptive studies, such as comparative studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IV&lt;/strong&gt; Evidence from expert committee reports or opinions or clinical experience of respected authorities or both&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; Directly based on category I evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; Directly based on category II evidence or extrapolated recommendation from category I evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; Directly based on category III evidence or extrapolated recommendation from category I or II evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;LB&lt;/strong&gt; Laboratory based&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An annotated clinical algorithm for the evaluation and management of individuals with suspected exercise-induced bronchoconstriction (EIB) in the presence or absence of chronic asthma is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate evaluation and management of individuals with suspected exercise-induced bronchoconstriction in the presence or absence of chronic asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Eucapnic voluntary hyperpnea (EVH) may cause substantial decreases in forced expiratory volume in 1 second (FEV&lt;sub&gt;1&lt;/sub&gt;) in a patient with impairment caused by airway inflammation; the EVH test should be performed with caution, especially in patients with an FEV&lt;sub&gt;1 &lt;/sub&gt;that is below 80% of predicted, and should not be performed on patients in whom the FEV&lt;sub&gt;1&lt;/sub&gt; is less than 70% of predicted. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methylxanthines exhibit a relatively narrow therapeutic index with potentially serious adverse events such as seizures. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Daily use of long-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonists (LABAs) and short-acting &amp;beta;&lt;sub&gt;2&lt;/sub&gt;-agonists (SABAs) may actually increase the severity of exercise-induced bronchoconstriction( EIB). Tolerance may increase with increasing use of SABAs and LABAs, potentially endangering patients with attacks of severe asthma at the time of greatest need for an effective SABA. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official American Academy of Allergy, Asthma and Immunology (AAAAI) or American College of Allergy, Asthma and Immunology (ACAAI) interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS, Rundell KW, Silvers WS, Storms WW, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Schuller DE, Spector SL, Tilles SA, Wallace D, Henderson W, Schwartz L, Kaufman D, Nsouli T, Shieken L, Rosario N, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. 2010 Dec;105(6 Suppl):S1-47. [493 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21167465&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Dec" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Academy of Allergy, Asthma and Immunology - Medical Specialty Society" /><FieldValue Value="American College of Allergy, Asthma and Immunology - Medical Specialty Society" /><FieldValue Value="Joint Council of Allergy, Asthma and Immunology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI), and the Joint Council of Allergy, Asthma and Immunology (JCAAI)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Joint Task Force on Practice Parameters&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Chief Editors&lt;/em&gt;: John M. Weiler, MD, MBA, President, CompleWare Corporation, Professor Emeritus, University of Iowa, Iowa City, Iowa; Sandra D. Anderson, PhD, DSc, Clinical Professor, Sydney Medical School, Royal Prince Alfred Hospital, Department of Respiratory and Sleep Medicine, Camperdown NSW, Australia; Christopher Randolph, MD, Clinical Professor of Pediatrics, Yale Affiliated Programs, Waterbury Hospital, Center for Allergy, Asthma and Immunology, Waterbury, Connecticut&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Co-editors&lt;/em&gt;: Sergio Bonini, MD, Professor of Medicine, Chair Allergology and Clinical Immunology, Second University of Naples, Naples, Italy; Timothy J. Craig, DO, Professor of Medicine and Pediatrics and Distinguished Educator, Pennsylvania State University, Hershey, Pennsylvania; David S. Pearlman, MD, Clinical Professor of Pediatrics, University of Colorado School of Medicine, Colorado Allergy and Asthma Centers, P.C., Denver, Colorado; Kenneth W. Rundell, PhD, FACSM, Director of Respiratory Research &amp;amp; the Human Physiology Laboratory Center for Healthy Families, Marywood University Professor of the Basic Sciences, The Commonwealth Medical College, Scranton, Pennsylvania; William S. Silvers, MD, Clinical Professor of Medicine, University of Colorado School of Medicine, Allergy, Asthma &amp;amp; Immunology Clinic of Colorado, P.C., Englewood, Colorado; William W. Storms, MD, Clinical Professor, University of Colorado Health Sciences Center, Practicing Allergist and Clinical Researcher, The William Storms Allergy Clinic, Colorado Springs, Colorado&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Task Force Reviewers&lt;/em&gt;: David I. Bernstein, MD, Professor of Medicine and Environmental Health, Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine University of Cincinnati, Cincinnati, Ohio; Joann Blessing-Moore, MD, Adjunct Clinical Professor, Department of Immunology, Stanford University Medical Center, Palo Alto, California; Linda Cox, MD, Associate Clinical Professor, Department of Medicine, Nova Southeastern University, Davie, Florida; David A. Khan, MD, Department of Medicine, Division of Allergy &amp;amp; Immunology, University of Texas Southwestern Medical Center, Dallas, Texas; David M. Lang, MD, Allergy/Immunology Section, Respiratory Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Richard A. Nicklas, MD, Clinical Professor of Medicine, George Washington Medical Center, Washington, DC; John Oppenheimer, MD, Department of Internal Medicine, New Jersey Medical School, Morristown, New Jersey; Jay M. Portnoy, MD, Section of Allergy, Asthma &amp;amp; Immunology, The Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri; Diane E. Schuller, MD, Professor of Pediatrics, Emeritus Chief of Allergy and Immunology, Department of Pediatrics, Pennsylvania State University, Milton S. Hershey Medical College, Hershey, Pennsylvania; Sheldon L. Spector, MD, Department of Medicine, UCLA School of Medicine, Los Angeles, California; Stephen A. Tilles, MD, Clinical Associate Professor of Medicine, University of Washington School of Medicine, Seattle, Washington; Dana Wallace, MD, Associate Clinical Professor, Department of Medicine, Nova Southeastern University, Davie, Florida&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Reviewers&lt;/em&gt;: William Henderson, MD, Seattle, Washington; Lawrence Schwartz, MD, PhD, Richmond, Virginia; David Kaufman, MD, Shreveport, Louisiana; Talal Nsouli, MD, Washington, DC; Lawrence Shieken, MD, Owings Mills, Maryland; Nelson Rosario, MD, Curitiba, Brazil&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Dr. Weiler is an employee of CompleWare Corporation. He also holds stock in CompleWare Corporation and Iowa Clinical Research Corporation, neither of which is an ACCME defined Commercial Interest, and he sold shares of Johnson &amp;amp; Johnson. CompleWare Corporation and Iowa Clinical Research Corporation provided contracted or granted services to MedImmune, Sandoz, GlaxoSmithKline, NIH, ALK, Pharmaxis, Novartis, Abbott, TEVA, Boehringer Ingelheim, Schering-Plough/Merck, Forest, Roxane Labs, Amgen, Repros, and Watson. Dr. Anderson is the inventor of the mannitol test and receives a percentage of the royalties paid to her employer, Sydney South West Area Health Service. Dr. Randolph has been a member of the speakers' bureau for Alcon, ISTA, GlaxoSmithKline, AstraZeneca, Schering-Plough/Merck, UCB, Wallace, Dey, Sciele, Baxter, Accredo, Critical Care, Genentech/Novartis, Sepracor, Meda, Sanofi-Aventis, TEVA, Pfizer, and Verus. He has acted as an advisor or consultant to AstraZeneca, Merck, GlaxoSmithKline, and Sanofi-Aventis and provided granted services to Schering-Plough and Novartis/Genentech. Dr. Bonini is a member of the expert forums and/or a speaker at sponsored symposia for ALK, Allergen Manufacturers, AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, Merck Sharp &amp;amp; Dohme, Novartis, Nycomed, Phadia, Schering-Plough, Sigma-Tau, Scalargenes, and UCB. Dr. Pearlman acts as an ad hoc consultant to AstraZeneca. He has also performed contract pharmaceutical research on EIB as a principal investigator between Colorado Allergy and Asthma Centers, P.C. (which pays him a salary) and each of the following companies: Merck, Novartis, Sepracor, GSK. Dr. Pearlman is also on the speakers' bureau of Merck. Dr. Storms has provided granted services to Alcon Labs, Amgen, and Sepracor. He has acted as an advisor or consultant to Alcon Labs, AstraZeneca, Consumer Reports/Consumers Union, Merck, Nexcura, Novartis, Sepracor, Strategic Pharmaceutical Advisors, TEVA, and the TREAT Foundation. He also serves on the speakers' bureau for Alcon Labs, AstraZeneca, Meda, Merck, Novartis, Sepracor, Strategic Pharmaceutical Advisors, and the TREAT Foundation. Dr. Rundell is currently employed by Pharmaxis Inc. Dr. Oppenheimer has performed research, acted as a consultant, or served on the speakers' bureau for AstraZeneca, Merck, GlaxoSmithKline, Alcon Labs, and Novartis. Drs. Craig, Silvers, Bernstein, Blessing-Moore, Cox, Khan, Lang, Nicklas, Portnoy, Schuller, Spector, Tilles, and Wallace have nothing to disclose.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.allergyparameters.org/file_depot/0-10000000/30000-40000/30326/folder/73825/2010Exercise.pdf&quot; title=&quot;Council of Allergy, Asthma, and Immunology (JCAAI) Web site&quot;&gt;Joint Council of Allergy, Asthma, and Immunology (JCAAI) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from JCAAI, 50 N. Brockway, Ste 3-3 Palatine, IL 60067.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on July 31, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. This copyrighted material may only be used personally and may not be distributed further. All rights reserved.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
